Impact of sitagliptin combination therapy and hypoglycemia in Japanese patients with type 2 diabetes: a multi-center retrospective observational cohort study

Tomoyuki Saito1,2*, Hirotoshi Ohmura1, Shuko Nojiri3 and Hiroyuki Daida1

Abstract

Background: Patients with diabetes are at higher risk of developing polypharmacy because of the high frequency of comorbidities. There have been several reports on the hypoglycemic risk of the combination of hypoglycemic agents and other medications. This study aimed to investigate the hypoglycemic risk of drug-drug interaction between sitagliptin and other oral hypoglycemic agents or antihypertensive agents in Japanese patients with type 2 diabetes.

Methods: From January 2010 to March 2012, a total of 3247 patients were recruited and evaluated at outpatient clinics at Juntendo University Hospital, other satellite hospitals, and private clinics. This study was a sub-analysis of the Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project. Participants were limited to those treated with oral hypoglycemic agents, excluding insulin users, to investigate the association of the first hypoglycemic events with oral hypoglycemic agents or other medications within 6 months after starting sitagliptin. The factors related to the first hypoglycemic event were analyzed using Cox regression analysis.

Results: In total, 2956 patients with a mean age of 65.1 ± 11.3 years were included. A total of 46 hypoglycemic events (1.6%) were observed. One patient had severe hypoglycemia followed by emergency transport to the hospital. Sitagliptin was not associated with hypoglycemia, but its combination with sulfonylurea (hazard ratio: 4.42, 95% confidential interval: 1.36–14.42) or β-blocker (hazard ratio, 3.50, 95% confidential interval: 1.54–7.96) was significantly associated with hypoglycemia.

Conclusions: The drug-drug interactions between sitagliptin and sulfonylurea or β-blocker likely increases the hypoglycemic risk in Japanese patients with type 2 diabetes. Pharmacists should consider potential adverse events from drug-drug interaction in type 2 diabetes with polypharmacy, particularly those who are managed by several doctors or clinics.

Keywords: Hypoglycemia, Dipeptidyl-peptidase IV inhibitors, Beta-blockers, Type 2 diabetes mellitus

* Correspondence: tomosai@juntendo.ac.jp
1Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan
2Department of Pharmacy, Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-Ku, Tokyo 113-8431, Japan

Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The prevalence of type 2 diabetes (T2DM) has been markedly increasing worldwide in recent decades [1]. In Japan, approximately 10 million people have T2DM, and it is estimated that just as many people potentially have T2DM [2]. T2DM is associated with reduced quality of life (QOL) and shortened life expectancy associated with microvascular complications [3–9]. Therefore, the ultimate goals of T2DM management are to maintain QOL and to prolong life expectancy by preventing vascular complications [10].

It has been reported that maintaining good glycemic control reduces the risk of microvascular complications [11–14]. However, previous clinical trials have failed to show the effects of intensive glycemic control on reducing the incidence of macrovascular complications [12, 14–16]. According to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, intensive glucose-lowering therapy failed to reduce major cardiovascular events. Moreover, severe hypoglycemia with intensive therapy resulted in increased mortality [17]. Therefore, the prevention of hypoglycemia is an important issue in the treatment of diabetes.

Patients with T2DM are more likely to have metabolic disorders such as hypertension, dyslipidemia, underlying insulin resistance, and other comorbidities. However, optimal comprehensive risk management including glucose, lipid, and blood pressure control demonstrated beneficial effects on decreasing the incidence of both microvascular and macrovascular complications and even on all-cause mortality [18–20]. Consequently, these patients are generally treated with many pharmacological compounds, commonly referred as “polypharmacy” [21, 22]. With this type of treatment, patients generally are at a high risk for drug-drug interactions. Polypharmacy is one of the risk factors associated with hypoglycemia as well as a lower education level, ethnicity, irregular meals/malnutrition, insulin and sulfonylurea therapy, cognitive impairment, depression and frailty. Among patients with T2DM, diabetic complications are more frequent in those with hypertension than in those without hypertension [7, 23–25]. However, a few antihypertensive agents have also been associated with an increased incidence of hypoglycemia and an increased risk of cardiovascular events [26]. Therefore, it is necessary to clarify the effects of the combined use of each OHA and antihypertensive drugs on hypoglycemia within a clinical setting.

Thus, the present study aimed to investigate the risk of hypoglycemia related to drug-drug interaction between OHAs and antihypertensive agents in Japanese patients with T2DM as a sub-analysis from the Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project (SPIRITS-J).

Methods
Setting and study cohort
The SPIRITS-J study was a multi-center retrospective observational cohort study designed to evaluate the efficacy and safety of sitagliptin supplementation for over 6 months. Participants were Japanese patients with T2DM who were treated with diet and exercise, other OHA combination therapy, and/or insulin therapy. All procedures were conducted according to the 1964 Declaration of Helsinki revised in 2013 and the Ethical Standards of the Responsible Committee on Human Experimentation. From January 2010 to March 2012, a total of 3247 patients were recruited and evaluated at outpatient clinics at Juntendo University Hospital, other satellite hospitals, and private clinics. We conducted a sub-group analysis in 2956 patients with T2DM who were excluded from insulin treatment (Fig. 1). In a study conducted by the Japanese Society of Glucose and Diabetes to investigate severe hypoglycemia, insulin was responsible for approximately 60% of severe hypoglycemia in patients with T2DM [15]. Hypoglycemia was excluded from the analysis because it was significantly affected by insulin treatment. This study was enrolled in the UMIN clinical trial registry (UMIN 000004121).

Data collection
Data were collected at four time points within 6 months after the initiation of sitagliptin (baseline, 1, 3, and 6 months). Baseline clinicodemographic data of all the patients enrolled in this study were collected, including age, sex, body mass index (BMI), diabetes duration, diabetes-related complications, medical history, lipid profile, random blood glucose, HbA1c, serum creatinine, and ingredient of medication for hypertension and diabetes. Blood test results were obtained from the medical records. Glucose and HbA1c were measured with standard techniques. The value of HbA1c (%) was estimated as the National Glycohemoglobin Standardization Program (NGSP) equivalent value (%) calculated using the formula HbA1c (%) = HbA1c (Japan Diabetes Society (%) + 0.4% [16]. The estimated glomerular filtration rate (eGFR) was calculated using the following formula: eGFR (mL/min/1.73 m²) = 194 × age − 0.287 × serum creatinine − 0.1094 (× 0.739 for women) [27].

Definition of hypoglycemia
We collected information on the first hypoglycemic event from patient self-report, medical records, and blood analysis from medical examinations with a blood glucose level of ≤60 mg/dL. Therefore, it includes subjective symptoms determined to be caused by hypoglycemia regardless of blood glucose level. The participants did not conduct self-monitoring of blood glucose (SMBG) because in the Japanese healthcare system,
SMBG is covered by insurance only in insulin users. Severe hypoglycemia represented hypoglycemic episodes that required the attention and assistance of another person.

**Definition of diabetic microvascular complications**
Retinopathy was defined as a progression from the absence of retinopathy to nonproliferative retinopathy or proliferative retinopathy, progression from nonproliferative retinopathy to proliferative retinopathy, or loss of vision due to retinopathy. Nephropathy is the progression from normal albuminuria to macroalbuminuria or from microalbuminuria to macroalbuminuria; an increase in serum creatinine concentration at least twice the study baseline; or end-stage renal failure, nephropathy, or neuropathy unrelated to peripheral neuropathy or spinal stenosis.

**Statistical analysis**
Results are presented as mean ± standard deviation (SD) or percentage (%). The HbA1c values observed at the four time points were calculated using a mixed-effects model to account for repeated measurements of participants and the random effects of observations. P-value was calculated using type III tests of fixed effects. Differences between baseline data and any observation points were examined for statistical significance using the Student’s t-test. Categorical variables were compared using the Chi-squared test and presented as absolute frequencies with percentages. The factors associated with hypoglycemic events were examined using Cox Regression analysis. A two-sided P-value of < 0.05 was considered statistically significant. The hazard ratio (HR) in cohort studies is positively correlated to the cumulative disease incidence [28]. Hence, it is important that enough events occur during the analysis period. In our previous study, we reported that blood glucose levels decreased significantly during the first month after the start of treatment with sitagliptin [6]. In addition, it has been found that hypoglycemia tends to increase during that period. Therefore, the Cox regression model was used considering the dynamic characteristics of the expected distribution. Moreover, it was confirmed that the proportional hazards in the Cox regression model were appropriate. All analyses were performed using SAS Ver. 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline clinicodemographic characteristics
Table 1 demonstrates the baseline clinicodemographic characteristics of the study patients. The mean T2DM duration was 10.2 ± 7.5 years, and the mean HbA1c level was 7.8 ± 1.2%. The mean age was 65.1 ± 11.3 years. In total, 459 (15.6%) patients had a history of coronary artery disease, and only approximately 15% of patients had at least one diabetic microvascular complication.

Table 2 demonstrates the usage of OHAs and anti-hypertensive agents in this study. Overall, 764 (25.5%) patients had treatment with sitagliptin monotherapy. The most common class of OHAs combined with sitagliptin was sulfonylurea (SU) (50.4%), followed by biguanide (39.5%), thiazolidinedione (TZD) (22.7%), alpha-glucosidase inhibitors (α-GI) (13.5%), and glinides (2.0%). For the anti-hypertensive agents, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (59.3%) and calcium channel blockers (46.9%) were the most commonly prescribed in this study.

Characteristics of the patients with hypoglycemia
A total of 46 hypoglycemic events (1.6%) were observed during the first 6 months after starting sitagliptin. One patient had severe hypoglycemia followed by emergency transport to the hospital. The patients with hypoglycemic events had a significantly higher number of combined OHAs (2.1 ± 1.0 vs. 1.3 ± 1.0, p < 0.0001) and significantly lower BMI (23.5 ± 3.9 vs. 25.1 ± 4.3, p = 0.0228) and plasma levels of UA (4.6 ± 1.4 vs. 5.2 ± 1.6, p = 0.0325) (Table 1). There was no significant difference in the duration of T2DM, although it tended to be longer in patients with hypoglycemic events (12.4 ± 7.2 vs. 10.2 ± 7.5, p = 0.0784). In addition, the prevalence of macrovascular and microvascular complications was not significantly different between the two groups. Regarding the OHAs and anti-hypertensive agents, the usage of SU, TZD, α-GI,
biguanide, and BB was significantly higher in patients with hypoglycemia.

In multivariate Cox regression model for the risk of hypoglycemia adjusted for sex, age, BMI, prescription number of OHAs, and eGFR, low BMI (HR: 0.86, 95% CI: 0.78–0.95), low uric acid (HR: 0.67, 95% CI: 0.49–0.90), use of SU (HR: 4.42, 95% CI: 1.36–14.42), and BB (HR: 3.50, 95% CI: 1.54–7.96) remained to be independent risk factors for hypoglycemia (Table 3).

**Discussion**

The present study investigated the risk of hypoglycemia from drug-drug interactions between sitagliptin and other OHAs or antihypertensive agents in Japanese patients with T2DM. In the SPIRITS-J study, the incidence of hypoglycemia in sitagliptin treatment combined with other OHAs was 1.6%. This result suggested the safety of sitagliptin as monotherapy or in combination with other OHAs in Japanese patients with T2DM. However, the multivariate Cox regression model demonstrated that the use of SU or BB were independent risk factors for hypoglycemia.

We have already reported that the risk of hypoglycemia associated with DPP-IV inhibitors is low, and that the risk increased when combined with SU. However, there are not enough reports on the hypoglycemic risk associated with drug combinations other than OHAs in patients with diabetes who have many complications. In particular, we investigated the drug-drug interactions with antihypertensive agents as a sub-analysis of SPIRITS-J.

Although maintaining good glycemic control reduces the risk of microvascular complications, intensive

---

**Table 2 Use of oral antidiabetic agents in the study subjects stratified by hypoglycemic event**

| Drugs          | Overall population N (%) | Non-hypoglycemia N (%) | Hypoglycemia N (%) | P-value* |
|----------------|----------------------------|-------------------------|--------------------|----------|
| SU            | 1468 (50.4)                | 1428 (49.8)              | 40 (87.0)          | < 0.0001 |
| TZD           | 662 (22.7)                 | 646 (22.5)               | 16 (34.8)          | 0.0490   |
| Glinide       | 59 (2.0)                   | 59 (2.1)                 | 0 (0.0)            |          |
| AGI           | 393 (13.5)                 | 378 (13.2)               | 15 (32.6)          | 0.0001   |
| Biguanide     | 1152 (39.5)                | 1125 (39.2)              | 27 (58.7)          | 0.0074   |
| β-blocker     | 318 (13.6)                 | 307 (13.4)               | 11 (27.5)          | 0.0098   |
| Diuretic      | 226 (9.7)                  | 222 (9.7)                | 4 (10.0)           | 0.9440   |
| ACE/ARB       | 1384 (59.3)                | 1362 (59.3)              | 22 (55.0)          | 0.5814   |
| CCB           | 1096 (46.9)                | 1079 (47.0)              | 17 (42.5)          | 0.5723   |

*Chi-squared tests were used in the analyses of categorical variables

---

**Table 3 Multivariate Cox regression model for hypoglycemia risk**

| Sitagliptin    | No. of cases | Person-years | Incidence rate per 100 population | HR  | 95% CI | P-value |
|----------------|--------------|--------------|-----------------------------------|-----|--------|---------|
| monotherapy    | 3            | 378          | 0.8                               | 1.00 |        |         |
| + SU           | 40           | 718          | 5.6                               | 4.42 (1.36–14.42) | 0.014 |
| + TZD          | 16           | 326          | 4.9                               | 0.55 (0.23–1.34)  | 0.189 |
| + GLINIDE      | 0            | 29           | 0.0                               | 0.90 (0.37–2.22)  | 0.820 |
| + AGI          | 15           | 193          | 7.8                               | 0.83 (0.35–2.01)  | 0.685 |
| + BIGUANIDE    | 27           | 566          | 4.8                               | 3.50 (1.54–7.96)  | 0.003 |
| Antihypertensive agents |     |              |                                    |     |        |         |
| + β-blocker    | 11           | 157          | 7.0                               | 1.67 (0.56–4.96)  | 0.359 |
| + Diuretic     | 4            | 111          | 3.6                               | 0.91 (0.42–1.97)  | 0.819 |
| + ACE/ARB      | 22           | 681          | 3.2                               | 0.97 (0.45–2.11)  | 0.942 |
| + CCB          | 17           | 541          | 3.1                               |        |        |         |

*Adjusted for sex, BMI, number of combined OHAs, and eGFR

SU sulfonylurea, TZD Thiazolidinedione, AGI Alpha-glucosidase inhibitors, ACE-I Angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blocker, CCB Calcium channel blocker, HR Hazard ratio, CI Confidence interval
glycemic control in the ACCORD trial resulted in increased all-cause and cardiovascular mortalities [18]. A possible explanation is that intensive glycemic control increased the risk of hypoglycemia and consequently increased the risk of major vascular events and death. Therefore, appropriate glycemic control without hypoglycemic events is important for preventing major cardiovascular events in patients with T2DM.

SU is widely used to treat T2DM because it lowers blood glucose levels by releasing insulin from beta cells in the pancreas [29]. DPP-4 inhibitors stimulate insulin secretion, suppress glucagon secretion, and reduce gastric emptying in a glucose-dependent manner [30]. Although severe hypoglycemia has been reported even with the single usage of SU [31], a meta-analysis of combination therapy efficacy of DPP-4 inhibitors with SU in patients with T2DM showed that the risk of hypoglycemia was increased by approximately 50% [32]. Therefore, the Japan Association for Diabetes Education and Care has recommended that decreasing the SU dosage should be considered in case of concomitant use with DPP-4 inhibitors [33]. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study recently reported that the combination of sitagliptin and SU did not increase the risk for severe hypoglycemia [34]. In our study, only one patient had severe hypoglycemia, but the concomitant use of SU with sitagliptin was an independent risk factor for hypoglycemia.

Polypharmacy is common in patients with T2DM because they often have co-morbidities; thus, it is necessary to consider the effect of hypoglycemia from drug-drug interactions [35]. Both hypertension and coronary artery disease (CAD) are frequent comorbidities in patients with T2DM. Moreover, diabetic complications are more frequent in T2DM patients with hypertension than in T2DM patients without hypertension [24, 25]. The efficacy of BB, which is one of the more popular anti-hypertensive agents, for preventing major cardiovascular events and improving prognosis has been established in patients with CAD [36, 37]. However, the benefit of BB in patients with T2DM has been controversial because BB is known to be associated with a risk for severe hypoglycemia [38]. In a post-hoc analysis of the ACCORD study, the use of BB in patients with T2DM was associated with not only the incidence of severe hypoglycemia, but also increased risk for cardiovascular events even in patients with CAD [36, 37]. Meanwhile, in patients with T2DM and atherosclerotic cardiovascular disease enrolled in the TECOS trial, which evaluated the effect of sitagliptin on cardiovascular outcomes, BB use was not associated with a risk for severe hypoglycemia but also was not associated with reduction of cardiovascular risk [39]. A recent meta-analysis reported that BB therapy in T2DM patients with stable CHD is associated with higher mortality [40]. This is supported by our findings that BB therapy in T2DM more likely increases the risk of hypoglycemia, consequently increasing the risk of major adverse events. Again, the benefit of BB in patients with T2DM remains unclear.

Insulin, SU, and alcohol are common causes of drug-induced hypoglycemia, but hypoglycemia occurs in around 10% of cases without the use of these drugs [41]. Among the 10% of alternate causes of drug-induced hypoglycemia, diuretics, BB, sympathomimetics, corticosteroids, and sex hormones are frequently reported. Carbohydrate metabolism may be adversely affected in patients with hypoglycemia, especially in those with diabetes or impaired glucose tolerance [42]. There are frequent reports that BB affect hypoglycemia, suggesting that they affect liver and kidney function through β receptors [41].

The combination of BB and DPP-IV inhibitors increases the risk of hypoglycemia, which can be explained by two factors. First, BB has been reported to mask the symptoms of hypoglycemia by reducing peripheral antiadrenergic effects [38, 43]. However, in the ACCORD trial, BB was reported to increase hypoglycemic events [26]. In our study, hypoglycemia also increased in patients using BB. The fact that BB did not mask hypoglycemic symptoms may be related to β1-receptor subtypes. Cardiac muscle has a large distribution of β1 receptors, and skeletal muscle has β3 receptors [44]. Therefore, since BBs used in recent years comprise several selective β1 receptors, it is difficult to mask hypoglycemic symptoms with the drugs. Frequently used carvedilol exhibits both nonselective β-blocking and weak α-receptor blocking effects; however, carvedilol has a weak β3 receptor blocking effect [45]. Second, selective β2-blockers suppress glycogen degradation and can counteract hypoglycemia owing to their effects on the liver and muscles [46]. Furthermore, β-receptor blockade suppresses glucagon secretion due to antidiadrenergic action [47]. There is currently no clinical basis for these pharmacological actions, and clinical verification is needed in the future.

Our study has some limitations. First, this was an observational study with no randomization and may have selection bias. Therefore, the results of this study should be interpreted cautiously. Second, there was little information about lifestyle, diet and exercise therapy, drug adherence, and confounding effects of other medications. Furthermore, information on the proportion and doses of OHAs and BB at 6 months was lacking. Third, laboratory tests were not standardized throughout the study. Fourth, the type of each drug, particularly, the type of BB, could not be identified. Among BB types, non-vasodilating BB has been suggested to be associated
with hyperglycemia, while vasodilating BB is associated with hypoglycemia [48]. Further prospective randomized studies are needed to elucidate the benefits and disadvantages of BB therapy in patients with T2DM.

Conclusion
The drug–drug interaction between sitagliptin and sulfonylurea or β-blocker likely increases the hypoglycemic risk in Japanese patients with type 2 diabetes. Pharmacists should consider potential adverse events from drug–drug interactions in patients with T2DM with polypharmacy, particularly those managed by several doctors or clinics.

Abbreviations
T2DM: Type 2 diabetes; QOL: Quality of life; ACCORD: Action to Control Cardiovascular Risk in Diabetes study; GLP-1: Glucagon-like peptide-1; GLP: Glucose-dependent insulinotropic polypeptide; OHAs: Oral hypoglycemic agents; HbA1c: Hemoglobin A1c; J-DOIT 3: The Japan Diabetes Optimal Integrated Treatment study; SPIRITS-J: The Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project; BMI: Body mass index; NGSP: The National Glycohemoglobin Standardization Program; eGFR: The estimated glomerular filtration rate; SMBG: Self-monitoring of blood glucose; SD: Standard deviation; SJ: Sulfonylurea; TZD: Thiazolidinedione; α-Gl: α-glucosidase inhibitors; BB: β-blockers; HR: Hazard ratio; TECOS: The Trial Evaluating Cardiovascular Outcomes with Sitagliptin study; CAD: Coronary artery disease

Acknowledgments
The authors would like to thank Ms. Keiko Wakana, Shoko Abukawa, Rinako Suga, Mayumi Fukuda, Atsuko Shiratori, and Yukari Nitta; Mr. Hiroshi Kitagawa and Genichiro Okazaki (Department for Lifetime Cancer Education, Juntendo University Graduate School of Medicine); and Ms. Megumi Matsumoto (Department of Cardiovascular Medicine) for their technical support. We also thank the participants of the study and Editage (www.editage.jp) for English language editing.

Authors’ contributions
Authors’ contributions: Mr. Tomoyuki Saito designed the study, and wrote the initial draft of the manuscript. Dr. Hirotsoshi Ohmura and Dr. Shuko Nohri contributed to analysis and interpretation of data, and assisted in the preparation of the manuscript. All other authors have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors approved the final version of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding
Financial support for this study was provided by the Waksman Foundation, Clinical Research Center, Juntendo University Graduate School of Medicine, and Center for Lifetime Cancer Education, Juntendo University Graduate School of Medicine. These centers received research funds from MSD, Daiichi Sankyo Inc., Novartis Pharmaceuticals, ONO Pharmaceutical Co., and Kyowa Hakko Kirin Co. The authors funded the article processing charges for this publication.

Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All procedures performed in this study, including human participants, complied with the ethical standards of the Institutional Research Committee (Juntendo Clinical Research and Testing Center of Juntendo University Hospital) and the 1964 Declaration of Helsinki and subsequent amendments or equivalent. Informed consent was obtained from all individual participants included in the study.

Consent for publication
Not applicable.

Competing interests
Hirotsoshi Ohmura has received lecture fees from Takeda Pharmaceutical Co., MSD KK, AstraZeneca KK, and Shionogi & Co. Ltd. and research funds from Pfizer Co., MSD KK, and Takeda Pharmaceutical Co. Ltd. Hiroyuki Daida has received lecture fees from AstraZeneca KK, MSD KK, Kowa Pharmaceutical Company Ltd., Sanofi-Aventis KK, GlaxoSmithKline KK, Shionogi & Co. Ltd., Daiichi-Sankyo Company, Limited, Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp, Pfizer Co. Ltd., and Astellas Pharma Inc. and research funds from Takeda Pharmaceutical Co. Ltd., Bristol-Myers Squibb Company, Nippon Boehringer Ingelheim Co. Ltd., Astellas Pharma Inc., Novartis Pharma KK, MSD KK, Sanofi-Aventis KK, Otsuka Pharmaceutical Co. Ltd., Dai nippon Sumitomo Pharma Co. Ltd., Pfizer Co. Ltd., Kowa Pharmaceutical Company Ltd., Shionogi & Co. Ltd., AstraZeneca KK, Teijin Limited, and Morinaga Milk Industry Co. Ltd. Tomoyuki Saito and Shuko Nohri have nothing to declare.

Author details
1Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan. 2Department of Pharmacy, Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-Ku, Tokyo 113-8431, Japan. 3Juntendo University, Medical Technology Innovation Center, 3-1-3 Hongo, Bunkyo-Ku, Tokyo 113-8431, Japan.

Received: 1 March 2020 Accepted: 11 May 2020

Published online: 04 June 2020

References
1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohrooge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabet.2018.02.023.
2. The Ministry of Health LaW. The National Health and nutrition survey; 2017. https://www.mhlw.go.jp/stf/houdou/0000177189.html.
3. Nathan DM, Genuith S, Lachin J, Cleary P, Crofford Q, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. https://doi.org/10.1056/NEJM199309303291401.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
5. Elder R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud. 2009;6:5–12. https://doi.org/10.1900/RDS.2009.6.6.
6. Ohmura H, Mita T, Taneda Y, Sugawara M, Funayama H, Matsuoka J, et al. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes. J Clin Med Res. 2015;7:211–9. https://doi.org/10.1016/j.jocmr.1983w.
7. Modan M, Malik H, Almog S, Lusky A, Estel D, Shefi M, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75:809–17. https://doi.org/10.1172/JCI111776.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ (Clinical research ed). 1998;317:703–13.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research ed). 1998;317:713–20.
10. Haneda M, Noda M, Orisaka H, Noto H, Yabe D, Fujita Y, et al. Japanese clinical practice guideline for diabetes 2016. J Diabetes Invest. 2018;6:567–97. https://doi.org/10.1111/jdi.12810.
11. Miyazaki Y, Murakami H, Hirata A, Fukuoka M, Masuda A, Ura N, et al. Effects of the angiotensin converting enzyme inhibitor temocapril on insulin
